Legend Biotech Corporation (LEGN) NASDAQ
35.98
-0.3(-0.83%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
35.98
-0.3(-0.83%)
Currency In USD
| Previous Close | 36.28 |
| Open | 34.98 |
| Day High | 37.46 |
| Day Low | 34.35 |
| 52-Week High | 45.3 |
| 52-Week Low | 16.24 |
| Volume | 4.08M |
| Average Volume | 2.25M |
| Market Cap | 6.65B |
| PE | -26.07 |
| EPS | -1.38 |
| Moving Average 50 Days | 23.71 |
| Moving Average 200 Days | 25.83 |
| Change | -0.3 |
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quar
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Exceeded 10,000 patients treated to date with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy manufacturing facility in the U
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2025 1:00 PM GMT
SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest co